• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

    11/14/24 4:23:02 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IDYA alert in real time by email
    SC 13G/A 1 sc13ga207422idya_11142024.htm AMENDMENT NO. 2 TO SCHEDULE 13G

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. 2)1

     

    IDEAYA Biosciences, Inc.

     (Name of Issuer)

    Common Stock, $0.0001 par value

     (Title of Class of Securities)

    45166A102

     (CUSIP Number)

    September 30, 2024

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 45166A102

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Fund, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         744,159  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              744,159  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            744,159  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. 45166A102

      1   NAME OF REPORTING PERSON  
             
            BVF I GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         744,159  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              744,159  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            744,159  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    3

    CUSIP No. 45166A102

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Fund II, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         574,278  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              574,278  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            574,278  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    4

    CUSIP No. 45166A102

     

      1   NAME OF REPORTING PERSON  
             
            BVF II GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         574,278  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              574,278  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            574,278  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    5

    CUSIP No. 45166A102

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Trading Fund OS LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         69,181  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              69,181  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            69,181  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    6

    CUSIP No. 45166A102

     

      1   NAME OF REPORTING PERSON  
             
            BVF Partners OS Ltd.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         69,181  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              69,181  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            69,181  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1%  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    7

    CUSIP No. 45166A102

     

      1   NAME OF REPORTING PERSON  
             
            BVF GP Holdings LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,318,437  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              1,318,437  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,318,437  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.6%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    8

    CUSIP No. 45166A102

     

      1   NAME OF REPORTING PERSON  
             
            BVF Partners L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,409,993  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              1,409,993  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,409,993  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.7%  
      12   TYPE OF REPORTING PERSON  
             
            PN, IA  

      

    9

    CUSIP No. 45166A102

     

      1   NAME OF REPORTING PERSON  
             
            BVF Inc.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,409,993  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              1,409,993  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,409,993  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.7%  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    10

    CUSIP No. 45166A102

     

      1   NAME OF REPORTING PERSON  
             
            Mark N. Lampert  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            United States  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,409,993  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              1,409,993  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,409,993  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.7%  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    11

    CUSIP No. 45166A102

    Item 1(a).Name of Issuer:

     

    IDEAYA Biosciences, Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    5000 Shoreline Court, Suite 300

    South San Francisco, California 94080

     

    Item 2(a).Name of Person Filing
    Item 2(b).Address of Principal Business Office or, if None, Residence
    Item 2(c).Citizenship

     

    Biotechnology Value Fund, L.P. (“BVF”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF I GP LLC (“BVF GP”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Biotechnology Value Fund II, L.P. (“BVF2”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF II GP LLC (“BVF2 GP”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Biotechnology Value Trading Fund OS LP (“Trading Fund OS”)

    PO Box 309 Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    Citizenship: Cayman Islands

     

    BVF Partners OS Ltd. (“Partners OS”)

    PO Box 309 Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    Citizenship: Cayman Islands

     

    BVF GP Holdings LLC (“BVF GPH”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    12

    CUSIP No. 45166A102

    BVF Partners L.P. (“Partners”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF Inc.

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Mark N. Lampert (“Mr. Lampert”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: United States

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, $0.0001 par value (the “Shares”)

     

    Item 2(e).CUSIP Number:

     

    45166A102

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / A non-U.S. institution, in accordance with Rule 13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    13

    CUSIP No. 45166A102

    Item 4.Ownership

     

    (a)Amount beneficially owned:

     

    As of the close of business on September 30, 2024, (i) BVF beneficially owned 744,159 Shares, (ii) BVF2 beneficially owned 574,278 Shares and (iii) Trading Fund OS beneficially owned 69,181 Shares.

     

    BVF GP, as the general partner of BVF, may be deemed to beneficially own the 744,159 Shares beneficially owned by BVF.

     

    BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 574,278 Shares beneficially owned by BVF2.

     

    Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 69,181 Shares beneficially owned by Trading Fund OS.

     

    BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 1,318,437 Shares beneficially owned in the aggregate by BVF and BVF2.

     

    Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 1,409,993 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, including the 22,375 Shares held in the Partners Managed Account.

     

    BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 1,409,993 Shares beneficially owned by Partners.

     

    Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 1,409,993 Shares beneficially owned by BVF Inc.

     

    The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

     

    14

    CUSIP No. 45166A102

    (b)Percent of class:

     

    The following percentages are based on 84,481,494 Shares outstanding as of August 2, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024.

     

    As of the close of business on September 30, 2024, (i) BVF beneficially owned less than 1% of the outstanding Shares, (ii) BVF2 beneficially owned less than 1% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own less than 1% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own less than 1% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 1.6% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 1.7% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (ii)Shared power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (iii)Sole power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    (iv)Shared power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the Shares, check the following [X].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    15

    CUSIP No. 45166A102

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    See Exhibit 99.1 to the Schedule 13G filed with the Securities and Exchange Commission on March 24, 2023.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    16

    CUSIP No. 45166A102

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    BIOTECHNOLOGY VALUE FUND, L.P.   BIOTECHNOLOGY VALUE TRADING FUND OS LP
           
    By: BVF I GP LLC, its general partner   By: BVF Partners L.P., its investment manager
          By: BVF Inc., its general partner
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF I GP LLC      
          BVF GP HOLDINGS LLC
    By: /s/ Mark N. Lampert    
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            Chief Executive Officer
             
    BIOTECHNOLOGY VALUE FUND II, L.P.    
          BVF PARTNERS L.P.
    By: BVF II GP LLC, its general partner    
          By: BVF Inc., its general partner
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF II GP LLC      
          BVF INC.
    By: /s/ Mark N. Lampert    
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF PARTNERS OS LTD.      
          /s/ Mark N. Lampert
    By: BVF Partners L.P., its sole member   MARK N. LAMPERT
    By: BVF Inc., its general partner    
             
    By:

    /s/ Mark N. Lampert

       
      Mark N. Lampert    
      President      

     

     

    17

     

    Get the next $IDYA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IDYA

    DatePrice TargetRatingAnalyst
    11/18/2024$51.00Overweight
    Stephens
    11/5/2024$27.00Outperform → Market Perform
    Leerink Partners
    10/24/2024$50.00Buy
    UBS
    10/15/2024Overweight
    Cantor Fitzgerald
    7/8/2024$50.00Outperform
    Mizuho
    3/8/2024$55.00Buy
    BTIG Research
    8/8/2023$33.00Outperform
    SVB Securities
    5/24/2023$32.00Buy
    Goldman
    More analyst ratings

    $IDYA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by IDEAYA Biosciences Inc.

      SCHEDULE 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

      5/14/25 12:26:18 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by IDEAYA Biosciences Inc.

      10-Q - IDEAYA Biosciences, Inc. (0001676725) (Filer)

      5/6/25 4:05:35 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)

      5/6/25 6:05:15 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Financials

    Live finance-specific insights

    See more
    • IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

      Phase 2 company-sponsored and IST neoadjuvant uveal melanoma (UM) clinical data update in 49 evaluable patients, demonstrates ~49% of patients with >30% tumor shrinkage by product of diameters, and ~61% eye preservation rate for enucleation patientsTargeting to initiate Phase 3 randomized registrational trial in neoadjuvant UM following finalization of the clinical protocol with FDAClinical endpoints supportive of full approval based on FDA guidance: Eye preservation rate as the primary endpoint for enucleation patients. Time to vision loss as the primary endpoint for plaque brachytherapy patients. No detriment to Event-Free-Survival (EFS) in the treatment arms is a secondary endpointDiscuss

      9/23/24 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

      SOUTH SAN FRANCISCO, Calif., Sept. 22, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, September 23, 2024, at 8:00 a.m. ET to report interim Phase 2 data for darovasertib and provide a regulatory update from FDA Type C meeting in neoadjuvant uveal melanoma (UM). Darovasertib is a potent and selective protein kinase C (PKC) inhibitor being developed to broadly address primary and metastatic UM.

      9/22/24 9:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer

      ~39% Overall Response Rate (ORR): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out of 18 evaluable MTAP-deletion urothelial and NSCLC patients~94% Disease Control Rate (DCR): 1 CR and 6 PRs and 10 SD by RECIST 1.1~78% of Patients with Tumor Shrinkage: 14 patients observed tumor shrinkage~81% ctDNA Molecular Response Rate (MRR): 13 of 16 patients with > 50% ctDNA reductionAE Profile: ~5.6% drug-related grade >3 AEs and no drug-related SAEs or discontinuations at 30 mg once-a-day expansion doseIDE397 expansion dose of 30 mg once-a-day achieved target drug coverage and plasma SAM pharmacodynamic reduction associated with preclinical tumor regressions~48k U.S. annual incidence of MTAP-

      7/8/24 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

      SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

      11/14/24 4:23:02 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

      SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

      11/14/24 3:13:37 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

      SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

      11/14/24 1:22:38 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

      ~$1.05 billion of cash, cash equivalents and marketable securities as of March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoingOver 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM trial; targeting median PFS results by YE 2025 to enable potential accelerated approval filingSuccessful FDA Type D meeting completed to finalize darovasertib Ph3 registrational trial design and received U.S. FDA Breakthrough Therapy Designation in neoadjuvant UMTargeting three darovasertib program clinical data updates at medical conferences in 2025, including 1L MUM mOS results in >40 patients and neoadjuvant UM data in >90

      5/6/25 6:05:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

      Targeting to evaluate IDE849 (SHR-4849) in SCLC, NETs, and other DLL3-upregulated solid tumors, and in combination with IDE161/PARG to potentially enhance durabilityTargeting to present clinical data of over 40 SCLC patients, including the dose escalation and expansion, from partner Hengrui at medical conference in Q3 2025SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to

      5/6/25 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

      SOUTH SAN FRANCISCO, Calif., April 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. Barclays Hosted: Peter Lawson's Catalyst & Key Debate Calls & Investor 1x1'sThursday, May 8th, 2025 at 11:00 AM ET Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Peter Lawson, D.Phil., Managing Director, Equity Research Analyst2025 RBC Capital Markets Global Healthcar

      4/28/25 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Leadership Updates

    Live Leadership Updates

    See more

    $IDYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Joshua Bleharski, Ph.D. as Chief Financial Officer.  Dr. Bleharski joins IDEAYA from J.P. Morgan, where he spent nearly 17 years advising clients in the biopharma sector on capital markets transactions, corporate strategy and other investment banking services. IDEAYA anticipates that Dr. Bleharski will complete the transition into his new role by early May. 

      2/10/25 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

      Brings over 20-year global commercialization experience in oncology with leading biopharmaceutical companies Gilead Sciences and Bristol Myers Squibb, including leadership of multiple commercial launches for products including Trodelvy® and Opdivo®SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Stu Dorman as Chief Commercial Officer. Mr. Dorman has a track record of commercial success in numerous specialty disease areas with over 20 years of oncology and hematology experience.

      11/18/24 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

      Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm

      9/18/24 6:00:00 AM ET
      $IDYA
      $GWPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Stephens initiated coverage on IDEAYA Biosciences with a new price target

      Stephens initiated coverage of IDEAYA Biosciences with a rating of Overweight and set a new price target of $51.00

      11/18/24 8:39:33 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded IDEAYA Biosciences from Outperform to Market Perform and set a new price target of $27.00

      11/5/24 7:22:44 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on IDEAYA Biosciences with a new price target

      UBS initiated coverage of IDEAYA Biosciences with a rating of Buy and set a new price target of $50.00

      10/24/24 6:22:17 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Beaupre Darrin

      4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

      2/28/25 6:03:47 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Dorman Stuart

      4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

      2/28/25 6:02:27 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Ruiz Briseno Andres

      4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

      2/28/25 6:02:04 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care